Summary
Global Markets Direct’s, ‘Pemphigus Vulgaris - Pipeline Review, H1 2016’, provides an overview of the Pemphigus Vulgaris pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Pemphigus Vulgaris, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Pemphigus Vulgaris and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Pemphigus Vulgaris
- The report reviews pipeline therapeutics for Pemphigus Vulgaris by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Pemphigus Vulgaris therapeutics and enlists all their major and minor projects
- The report assesses Pemphigus Vulgaris therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Pemphigus Vulgaris
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Pemphigus Vulgaris
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Pemphigus Vulgaris pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
Almirall, S.A.
Biogen, Inc.
F. Hoffmann-La Roche Ltd.
HanAll Biopharma Co., Ltd.
Immunomedics, Inc.
Novartis AG
Principia Biopharma Inc.
'
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Pemphigus Vulgaris Overview 6
Therapeutics Development 7
Pipeline Products for Pemphigus Vulgaris - Overview 7
Pipeline Products for Pemphigus Vulgaris - Comparative Analysis 8
Pemphigus Vulgaris - Therapeutics under Development by Companies 9
Pemphigus Vulgaris - Therapeutics under Investigation by Universities/Institutes 10
Pemphigus Vulgaris - Pipeline Products Glance 11
Late Stage Products 11
Clinical Stage Products 12
Early Stage Products 13
Unknown Stage Products 14
Pemphigus Vulgaris - Products under Development by Companies 15
Pemphigus Vulgaris - Products under Investigation by Universities/Institutes 16
Pemphigus Vulgaris - Companies Involved in Therapeutics Development 17
Almirall, S.A. 17
Biogen, Inc. 18
F. Hoffmann-La Roche Ltd. 19
HanAll Biopharma Co., Ltd. 20
Immunomedics, Inc. 21
Novartis AG 22
Principia Biopharma Inc. 23
Pemphigus Vulgaris - Therapeutics Assessment 24
Assessment by Monotherapy Products 24
Assessment by Target 25
Assessment by Mechanism of Action 27
Assessment by Route of Administration 29
Assessment by Molecule Type 31
Drug Profiles 33
ADP-31415 - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Cellular Immunotherapy for Pemphigus Vulgaris - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
DPC-006 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
HL-161 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
mycophenolate mofetil - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
PRN-1008 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
rituximab - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
VAY-736 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
veltuzumab - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Pemphigus Vulgaris - Recent Pipeline Updates 49
Pemphigus Vulgaris - Dormant Projects 54
Pemphigus Vulgaris - Discontinued Products 55
Pemphigus Vulgaris - Product Development Milestones 56
Featured News & Press Releases 56
Jan 07, 2016: Principia Biopharma Advances BTK Inhibitor Program in Autoimmune Disease and FGFR Inhibitor Program in Oncology 56
Aug 25, 2015: Genentech Initiates Phase III Trial of Rituxan for Rare, Autoimmune Disease: Pemphigus Vulgaris 56
Appendix 58
Methodology 58
Coverage 58
Secondary Research 58
Primary Research 58
Expert Panel Validation 58
Contact Us 58
Disclaimer 59
List of Tables
Number of Products under Development for Pemphigus Vulgaris, H1 2016 7
Number of Products under Development for Pemphigus Vulgaris - Comparative Analysis, H1 2016 8
Number of Products under Development by Companies, H1 2016 9
Number of Products under Investigation by Universities/Institutes, H1 2016 10
Comparative Analysis by Late Stage Development, H1 2016 11
Comparative Analysis by Clinical Stage Development, H1 2016 12
Comparative Analysis by Early Stage Development, H1 2016 13
Comparative Analysis by Unknown Stage Development, H1 2016 14
Products under Development by Companies, H1 2016 15
Products under Investigation by Universities/Institutes, H1 2016 16
Pemphigus Vulgaris - Pipeline by Almirall, S.A., H1 2016 17
Pemphigus Vulgaris - Pipeline by Biogen, Inc., H1 2016 18
Pemphigus Vulgaris - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 19
Pemphigus Vulgaris - Pipeline by HanAll Biopharma Co., Ltd., H1 2016 20
Pemphigus Vulgaris - Pipeline by Immunomedics, Inc., H1 2016 21
Pemphigus Vulgaris - Pipeline by Novartis AG, H1 2016 22
Pemphigus Vulgaris - Pipeline by Principia Biopharma Inc., H1 2016 23
Assessment by Monotherapy Products, H1 2016 24
Number of Products by Stage and Target, H1 2016 26
Number of Products by Stage and Mechanism of Action, H1 2016 28
Number of Products by Stage and Route of Administration, H1 2016 30
Number of Products by Stage and Molecule Type, H1 2016 32
Pemphigus Vulgaris Therapeutics - Recent Pipeline Updates, H1 2016 49
Pemphigus Vulgaris - Dormant Projects, H1 2016 54
Pemphigus Vulgaris - Discontinued Products, H1 2016 55
List of Figures
Number of Products under Development for Pemphigus Vulgaris, H1 2016 7
Number of Products under Development for Pemphigus Vulgaris - Comparative Analysis, H1 2016 8
Number of Products under Development by Companies, H1 2016 9
Comparative Analysis by Early Stage Products, H1 2016 13
Assessment by Monotherapy Products, H1 2016 24
Number of Products by Targets, H1 2016 25
Number of Products by Stage and Targets, H1 2016 25
Number of Products by Mechanism of Actions, H1 2016 27
Number of Products by Stage and Mechanism of Actions, H1 2016 27
Number of Products by Routes of Administration, H1 2016 29
Number of Products by Stage and Routes of Administration, H1 2016 29
Number of Products by Molecule Types, H1 2016 31
Number of Products by Stage and Molecule Types, H1 2016 31
